Aliases:This biomarker is also known as:
- CC chemokine CCL28,
- small-inducible cytokine A28,
- small inducible cytokine subfamily A (Cys-Cys), member 28,
- C-C motif chemokine 28,
- Protein CCK1,
- Mucosae-associated epithelial chemokine,
- chemokine (C-C motif) ligand 28,
- Small-inducible cytokine A28,
- small inducible cytokine A28,
- mucosae-associated epithelial chemokine,
- chemokine (C-C motif) ligand 28 splice variant chi,
CCL28 is a member of the small cytokine CC subfamily, and is involved in immunoregulatory and inflammatory processes. CC cytokines are characterized by two adjacent cysteines. CCL28 functions as a chemotactic factor for resting CD4 or CD8 T cells and eosinophils. CCL28 binds to CCR3 and CCR10 and induces calcium mobilization in a dose-dependent manner.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
CCL28 was present at higher levels among cases compared to controls with reasonable AUC values.
CCL28 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.